Blood-brain barrier (BBB) nicotine transfer has been well documented in view of the fact that this alkaloid is a cerebral blood flow marker. However, limited data are available that describe BBB penetration of the major tobacco alkaloids after chronic nicotine exposure. This question needs to be addressed, given long-term nicotine exposure alters both BBB function and morphology. In contrast to nicotine, it has been reported that cotinine (the major nicotine metabolite) does not penetrate the BBB, yet cotinine brain distribution has been well documented after nicotine exposure. Surprisingly, therefore, the literature indirectly suggests that central nervous system cotinine distribution occurs secondarily to nicotine brain metabolism. The aims of the current report are to define BBB transfer of nicotine and cotinine in naive and nicotine-exposed animals. Using an in situ brain perfusion model, we assessed the BBB uptake of 3 H]cotinine BBB transfer is not altered by chronic nicotine exposure. To our knowledge, this is the first report detailing the uptake of nicotine and cotinine after chronic nicotine exposure and quantifying the rate of BBB penetration by cotinine.
The blood to brain transfer kinetics of nicotine and its primary metabolite cotinine is a determinant factor for central nervous system (CNS) concentrations. For CNS access, nicotine and/or cotinine must traverse the specialized neurovascular endothelium, which theoretically can limit plasma to brain distribution. Kinetic transfer at the blood-brain barrier (BBB) is limited by endothelium that is connected through tight junctions (zonula occludens), the absence of paracellular openings, a lack of pinocytocis activity, enzymatic restrictions, and significant protein-mediated efflux (Begley and Brightman, 2003) .
Once nicotine penetrates the CNS, it acts as an agonist at the ␣4␤2 and ␣3␤2 subtypes of nicotinic acetylcholine receptors (nAChRs) in the ventral tegmental area, an action that evokes dopamine release in the nucleus accumbens (Di Chiara, 2000) . Although the addictive mechanisms of nicotine are under intensive investigation, the degree to which cotinine modifies nicotine addiction is controversial (Buccafusco and Terry, 2003) . In support of cotinine addiction theories, cotinine has been shown to activate the superior cervical ganglion (Schroff et al., 2000) , act as an agonist (with weak affinity) at the human ␣7 nAChR (Briggs and McKenna, 1998) , and stimulate dopamine release from rat striatal synaptosomes at doses 30 to 50 times greater than nicotine (Crooks et al., 1997) . Yet other data demonstrate that cotinine lacks significant whole brain cholinergic effect (Linville et al., 1993; Radek, 1993) .
The rapid blood-brain transfer of nicotine in naive animals has been well documented due to the fact that it is a known cerebral blood flow marker (Ohno et al., 1979; Suzuki et al., 1984; Todd and Weeks, 1996; Tomiyama et al., 1999) . However, limited data are present in the literature regarding nicotine BBB penetration after chronic nicotine exposure. Such studies are of significant importance given long-term nicotine exposure changes both BBB function and morphology. Specifically, nicotine has been shown to increase BBB endothelium microvilli formation (Booyse et al., 1981) , decrease in vitro zonula occluden-1 expression and diminish the levels and/or function of nAChRs located at the BBB (Abbruscato et al., 2002) , down-regulate Na,K,2Cl cotransporters , and down-regulate ␣2 Na,K-ATPase (Wang et al., 1994) .
In contrast to that of nicotine, the rate of uptake for coti-nine across the BBB is poorly defined. Literature reports on the ability of cotinine to penetrate the BBB to any significant degree are conflicting (Halldin et al., 1992; Riah et al., 1998) . Cotinine has been detected in brain after nicotine exposure (Crooks et al., 1997; Riah et al., 1998) , but indirect data suggest that this CNS presence may be the result of central nicotine metabolism by CYP2B1, a monooxygenase enzyme which has been detected in rat brain and shown to be induced by chronic nicotine (Jacob et al., 1997; Miksys et al., 2000) . The current report documents the blood to brain transfer of cotinine using the in situ brain perfusion model and compares the kinetics with that of nicotine. Furthermore, the degree and rate of cotinine (as well as nicotine) brain uptake was evaluated in naive and chronic nicotine-exposed animals using the same model.
Materials and Methods
The brain uptake of [ 3 H]nicotine and [ 3 H]cotinine was assessed using the in situ rat brain perfusion technique with modifications described (Smith, 2003) . In this study, perfusions of 15 to 60 s were used to determine tracer brain uptake rates in naive rats and those exposed to nicotine for 28 days. Chronic nicotine administration was comparable with previous methodology that provided nicotine and cotinine blood levels similar to those found in heavy smokers (nicotine ϳ80 -100 ng/ml; cotinine Ͼ250 ng/ml) (Hawkins et al., 2004; Lockman et al., 2005) . Briefly, osmotic minipumps (Alzet 2ML4, 28-day capacity: 2000 l) were loaded with S-(Ϫ)nicotine (42 mg; sterile; free base/dissolved in sterile saline) and released over 28 days at a rate of 2.5 l/h. Prior to implantation, minipumps were primed in sterile saline at 37°C for 24 h according to the manufacturer's specifications. Pumps were then removed and immediately implanted interscapularly (Castagnoli et al., 2002) into male Fischer-344 rats (220 -330 g; Charles River Laboratories, Kingston, NY). The surgical procedure consisted of anesthesia (sodium pentobarbital, 50 mg/kg), rectal temperature monitoring, and maintenance of core body temperature at 37°C by a heating pad feedback device (YSI Indicating Controller; YSI Inc., Yellow Springs, OH). A small thoracolumbar subcutaneous incision (ϳ4 cm) was made, and a pocket projecting rostrally, large enough to accommodate the minipump, was opened using a blunt hemostat. Manual insertion of the minipump was completed under sterile conditions and the wound closed with staples. Rats were monitored during recovery after which they were allowed ad libitum access to food and water. Nicotine levels (ϳ72 ng/ml) were verified by high-performance liquid chromatography in a subset of animals on day 28. Cotinine levels (469 Ϯ 27 ng/ml) were also verified by enzyme immunoassay (Cozart Bioscience Ltd, Oxfordshire, UK) prior to in situ perfusion procedures to ensure adequate nicotine exposure.
Perfusion Procedure. After 28 days of nicotine exposure, animals were anesthetized with sodium pentobarbital (50 mg/kg; intraperitoneal). A PE-60 catheter filled with heparinized saline (100 units/ml) was placed into the left common carotid artery after ligation of the left external carotid, occipital, and common carotid arteries (common carotid artery ligation was accomplished caudally to the catheter implantation site). The pterygopalatine artery was left open. Rat body temperature was monitored and maintained at 37°C by a heating pad and feedback device (YSI Indicating Controller; YSI Inc.). The buffered physiologic perfusion fluid used was titrated to pH 7.4 (osmolarity ϳ290 mOsm; verified) and contained 128 mM NaCl, 2.4 mM NaPO 3 , 29.0 mM NaHCO 3 , 4.2 mM KCl, 1.5 mM CaCl, 0.9 mM MgCl, and 9 mM D-glucose with 0.33 Ci/ml [ 14 C]sucrose and either 0.5 Ci/ml [ 3 H]nicotine or 1.0 Ci/ml [ 3 H]cotinine. Immediately prior to perfusion, the fluid was filtered and warmed to 37°C and gassed with 95% air and 5% CO 2 .
The perfusion fluid was infused into the left carotid artery via infusion pump for 15 to 60 s at 10 ml/m (Harvard Apparatus, Holliston, MA). This level of flow maintained carotid artery pressure at ϳ120 mm Hg. Rats were decapitated, the brain rapidly removed from the skull, and the perfused hemisphere dissected on ice after removal of the arachnoid membrane and meningeal vessels. Brain regions and perfusion fluid samples were digested overnight at 50°C in 1 ml of 1 M piperidine. Dual-labeled scintillation counting of brain and perfusate samples was then accomplished with correction for quench, background, and efficiency (LS6500 Multipurpose scintillation counter; Beckman Coulter, Fullerton, CA).
Kinetic Analysis. Concentrations of tracer in brain and perfusion fluid are expressed as disintegrations per minute per gram of brain jpet.aspetjournals.org or disintegrations per minute per milliliter of perfusion fluid, respectively. A brain/perfusate distribution volume was ascertained as described (Smith, 2003 ) from the following relationship:
where Q* is the quantity of tracer in brain (disintegrations per minute per gram) at the end of perfusion, and C* is the perfusion fluid concentration of tracer (disintegrations per minute per milliliter). Unidirectional uptake transfer constants, or K in , were then calculated from brain distribution volume versus time, using linear regression analysis (Smith, 2003) by eq. 2: (Lockman et al., 2003) .
K in values for [ 3 H]nicotine and [ 3 H]cotinine were converted to apparent cerebrovascular permeability-surface area products (PA) using the Crone-Renkin equation (Smith, 2003) :
Statistical Analysis. Data presented are from total left hemispheric brain, unless otherwise specified. Brain PA and K in were evaluated by Student's t test, and regional data were evaluated by one-way analysis of variance followed by Bonferroni's multiple comparison test. Regional differences in K in or PA were evaluated individually by a Student's t test (two-tailed). Differences were considered statistically significant at p Ͻ 0.05. Errors are reported as standard error of mean (GraphPad Prism version 4.0 for Windows; GraphPad Software, San Diego, CA).
Results

Brain uptake rates of [
3 H]nicotine and [ 3 H]cotinine were evaluated in both naive rats and rats exposed to nicotine (28 days at 4.5 mg/kg/day; plasma levels ϳ72 ng/ml) and cotinine (the presence of cotinine was from endogenously metabolized nicotine; 469 Ϯ 27 ng/ml). Brain uptake of [ 3 H]nicotine was evaluated with short perfusions of 15 s (Figs. 1A and 2 ) to prevent significant brain to blood efflux (i.e., unilateral uptake) and CNS metabolism of nicotine to cotinine. No significant difference in total brain [ 3 H]nicotine uptake were noted between naive (3.11 Ϯ 0.42 ϫ 10 Ϫ2 ml/s/g) and nicotineexposed (3.31 Ϯ 1.1 ϫ 10 Ϫ2 ml/s/g) rats (Fig. 1A) . To assess whether chronic nicotine exposure altered flow in our model, we evaluated brain uptake of [ 3 H]diazepam (Lockman et al., 2003) . As seen in Fig. 1B , no apparent flow alterations were noted between control (5.11 Ϯ 0.98 ϫ 10 Ϫ2 ml/s/g) and nicotine exposure (4.61 Ϯ 0.81 ϫ 10 Ϫ2 ml/s/g). The increased cerebral perfusion flow rate with [ 3 H]diazepam compared with [ 3 H]nicotine was found to be consistent with previously published perfusion flow data (Lockman et al., 2003; Smith, 2003) .
Regional brain analyses confirmed the lack of significant differences in [ 3 H]nicotine uptake into brain between naive and nicotine-exposed animals (Fig. 2). [ 3 H]Nicotine uptake in this study showed a pattern of uptake influenced by cerebral perfusion flow commonly found in the in situ perfused brain, where flow rates are found to be highest in the cortical regions (4.02 Ϯ 0.59 ϫ 10 Ϫ2 ml/s/g) and lower in the cerebellum (1.39 Ϯ 0.40 ϫ 10 Ϫ2 ml/s/g) and pons medulla (0.94 Ϯ 0.21 ϫ 10 Ϫ2 ml/s/g) (Smith, 2003) .
Fig. 2. Regional brain uptake of [
3 H]nicotine in naive rats and in nicotine-exposed rats (28 days ϫ 4.5 mg/kg/day). No significant changes were noted throughout all brain regions with the exception of the caudate putamen region ‫,ء(‬ p Ͻ 0.05). These data support those shown in Fig. 1 Fig. 3, A and B, the total brain uptake of [ 3 H]cotinine in animals subjected to chronic nicotine exposure (K in : 2.07 Ϯ 0.25 ϫ 10 Ϫ3 ml/s/g; PA: 2.11 Ϯ 0.25 ϫ 10 Ϫ3 ml/s/g) was found not to be significantly altered from control in whole brain (K in : 2.03 Ϯ 0.17 ϫ 10 Ϫ3 ml/g; PA: 2.06 Ϯ 0.17 ϫ 10 Ϫ3 ml/s/g) or regionally (Fig. 4) ml/s/g and PA: 2.17 Ϯ 0.27 ϫ 10 Ϫ3 ml/s/g; pons medulla K in : 1.60 Ϯ 0.19 ϫ 10 Ϫ3 ml/s/g and PA 1.62 Ϯ 0.19 ϫ 10 Ϫ3 ml/s/g). Vascular volume measurements after chronic nicotine exposure (using the impermeant marker [
14 C]sucrose) were also assessed concurrently in all experiments to determine BBB integrity (i.e., increased vascular volumes would indicate BBB disruption). With regard to nicotine and cotinine exposure, total brain vascular volume did not significantly vary between control (1.33 Ϯ 0.34 ϫ 10 Ϫ2 ml/g) and nicotineexposed groups (1.31 Ϯ 0.30 ϫ 10 Ϫ2 ml/g) (Fig. 3, A and B) . Also, no regional alterations in vascular volume were noted (Fig. 5) .
Discussion
Data presented in the current study demonstrate: 1) [ 3 H]nicotine blood to brain transfer is not altered after chronic nicotine exposure as measured in the in situ perfusion model, 2) [ 3 H]cotinine penetrates the BBB, and 3) similar to the data found for [
3 H]nicotine, [ 3 H]cotinine BBB transfer is not altered by chronic nicotine exposure (Fig. 6) . To our knowledge, this is the first report detailing brain uptake of nicotine and cotinine following chronic in vivo nicotine exposure and also a rate determination study of cotinine BBB penetration.
Chronic tobacco exposure decreases cerebral blood flow (Rogers et al., 1983) and accordingly diminishes BBB trans- fer of compounds that are flow-dependent (i.e., extraction approximately Ն80%). Therefore, to determine whether nicotine has a similar effect, we evaluated the uptake of [ 3 H]diazepam in both naive and nicotine-exposed animals. It appears from our data that cerebral perfusion flow values are not significantly altered in the presence of chronic nicotine exposure. However, our data do not preclude the influence of effects on cerebral blood flow due to in situ model limitations, including secondary loss of cerebral blood flow (such as the absence of autoregulatory factors in a pump-driven organ perfusion flow system).
Earlier work by the group of Ghosheh on the brain distribution of nicotine found increased levels (i.e., distribution) of nicotine in brain following chronic nicotine exposure. The authors suggested several rationales for the increased nicotine brain distribution including alterations in BBB transfer rates, increased nAChR binding, and sequestration of nicotine in glial cytosol through its protonation (pKa ϭ 9.13, glial cytosol pH ϳ6.5-7.0) (Ghosheh et al., 2001) . Our data explored the first rationale proposed by Ghosheh's group. In our experiments, the BBB transfer of [ 3 H]nicotine was found to be ϳ70 to 80% of flow ([ 3 H]diazepam uptake) and consequently may be influenced by flow alterations. Therefore, if chronic nicotine exposure resulted in BBB alterations that may influence blood to brain transfer of [ 3 H]nicotine, such changes should be apparent using the in situ model. Our 3 H]cotinine in naive rats and in nicotine-exposed rats (28 days ϫ 4.5 mg/kg/day). Similar to whole brain studies, no significant changes were noted with the exception of the hippocampus region ‫,ء(‬ p Ͻ 0.05). All data represent mean Ϯ S.E.M.; n ϭ 3 to 5 for all points. 3 H]nicotine brain uptake after chronic nicotine exposure either in whole brain or in any measured brain region. We believe the increased CNS distribution of nicotine seen in previous studies may be from the result of either increased neuronal binding or glial sequestration.
As a major metabolic pathway in the periphery, nicotine primarily (ϳ80%) undergoes liver aldehyde oxidation via CYP2A6 to form cotinine in humans (Messina et al., 1997; Yamanaka et al., 2004) and in rats (homolog CYP2B1) (Hammond et al., 1991; Nakayama et al., 1993) . There is controversy as to whether cotinine penetrates the BBB from plasma (Halldin et al., 1992; Riah et al., 1998) or whether the detection of cotinine in brain is solely the result of central nicotine metabolism. Recently, nicotine has been shown to be metabolized in rat brain (Jacob et al., 1997) via CYP2B1 (human homolog CYP2B6), and this process is up-regulated after chronic nicotine exposure (Miksys et al., 2000) (although the amount of nicotine metabolism in brain has not been elucidated). Therefore, to determine whether brain cotinine concentrations are also altered by BBB transfer in naive and nicotine-exposed animals, we evaluated the brain uptake of
Contrary to previous reports, our data demonstrate there is significant BBB transfer of cotinine that is generally homogeneous among brain regions. Comparison of the PA and log P for [ 3 H]cotinine suggests [ 3 H]cotinine crosses the BBB by passive diffusion (Ghosheh et al., 2001; Smith, 2003) . This rate of [ 3 H]cotinine BBB penetration is significant, considering it is comparable with other neuroactive molecules including theophylline, adenosine, and choline (Smith, 2003) .
Our evaluation of unidirectional influx of cotinine and nicotine into brain further suggests that the nicotine metabolite penetrates the BBB significantly. The average cotinine plasma levels measured in heavy smokers were found to be fairly stable and range from 250 to 350 ng/ml (Benowitz et al., 1983; Paoletti et al., 1996) . Calculation of influx (influx ϭ C pl ϫ PA) reveals that cotinine enters the brain at a rate of 0.5 to 0.7 ng/s/g or ϳ43 to 61 g/g/day. On the other hand, nicotine plasma levels vary significantly between 10 and 50 ng/ml in smokers (Russell and Feyerabend, 1978; Benowitz et al., 1982) , following increment peaks of 5 to 30 ng/ml per jpet.aspetjournals.org cigarette (t 1/2 ϳ 2 h) (Isaac and Rand, 1972; Armitage et al., 1975) . Therefore, assuming that the highest average nicotine plasma level is 40 to 50 ng/ml over a 24-h period, the BBB influx of nicotine would approximate 1.32 to 1.65 ng/s/g or 114 to 143 g/g/day. Comparison of influx data measured for the two compounds suggests that cotinine enters brain at amounts approximately 40% than that of nicotine regardless of prior nicotine exposure. Although our studies did not include measurement of pharmacological activity, the data suggest that cotinine may penetrate the BBB to a degree that would allow central action.
Data presented in the current study also demonstrate that vascular volumes are not altered after chronic nicotine exposure. These data are consistent with our recently published work (Lockman et al., 2005) and other reports demonstrating that chronic pharmacological relevant nicotine exposure does not alter functional BBB integrity of epithelium (Minty et al., 1984) or endothelium in vivo (Booyse et al., 1981; Allen et al., 1988; Myers et al., 1988) . Taken together, these data suggest that chronic nicotine-exposed animals retain an operative BBB.
In summary, our data demonstrate that both cotinine and nicotine significantly penetrate the BBB and that transfer rates are not affected by chronic heavy nicotine exposure. This current report will be expanded further by compartmental (both central and peripheral) pharmacokinetic modeling for both nicotine and cotinine. Care must be taken to elucidate the distribution sites in such modeling studies (e.g., nicotine/cotinine accumulation in plasma, endothelium, glia, neurons, and extracellular fluid as measured in the central compartment). Such future work may significantly increase our understanding of the distribution of free drug in brain and may help elucidate the complex action of nicotine and its major metabolite in a tobacco-consuming human population.
